Top Stories News

The UK government intends to take steps to attract drug research and development projects back to the UK.

The Stentys Self-Apposing Stent clinical trials show low death rates in patients following severe heart attack.

The executive vice president chief operating officer of the company, which specialises in drug formulations for unmet medical needs, is leaving for other opportunities.

Drug formulation PRTX-100 passed a scheduled interim data safety monitoring committee meeting.

OMP-52M51 is a therapeutic that targets cancer stem cells.

Tests involving the delivery of an immune system-enhancing drug to patients suffering from colorectal cancer have shown promise.

A new independent company called AbbVie has been formed to take forward Abbott's research-based pharmaceuticals business.

Saudi Arabia is one of the largest pharmaceutical markets in the Middle East and is due to experience steady growth.

Dr Joerg Reinhardt will be the new chairman of Novartis, succeeding Dr Daniel Vasella.

OvaSciences enjoyed a strong year with most of its R&D spend coming on CROs for a major new trial.

Development of the clinical candidate RE-021 is being handled by Retrophin, which also has commercialisation rights.

The Digital Pharma Experience takes place in Prague in May.

Diagnovus' new gene expression assay aims to provide more accurate risk profiles for DLBCL patients.

Roche has acquired global licencing rights for the acromegaly treatment, which is in phase three trials.

The two firms are collaborating to improve their green performance and enzyme process development.

Neurotrophic keratitis patients to get eyedrop treatment.

New treatment to help mild sufferers of ulcerative colitis.

Cancer research organisation will include six new members.

BioMed has launched its new pharmacy management system RxVector.

New diagnostic tests to be developed as a result of funding.

Affymetrix and DNA Link team up to consumerise DNA identification technology .

Genentech has seen positive results in Phase III trials of its CLL drug.

Vertex will continue with its research into cystic fibrosis, hepatitis C and autoimmune diseases this year.

New innovations in the medical adhesives sector will accelerate the move away from the use of sutures and staples.

Japan recognises birinapant innovation.

Asia to get new visualisation technology from Sectra.

BioSante and ANI Pharmaceuticals arrange special meetings for merger.

US foundation commits £25 million to fighting pancreatic cancer.

Avoca's outsourcing group has set out its key goals for 2013.

Patients will no longer have to undergo painful autografting for second-degree burns.

BioChemics ventures into wound treating market.

Independent pharmaceutical companies to discuss the changing industry.

Scientific medal goes to Dr Lucy Shapiro of Anacor Pharmaceuticals.

Spectrum announces new arrival plus its plan for the next five years.

Device outsourcing set to rise exponentially between now and 2018.

Number of pharmaceutical companies using outsourcing increases.

A Frost & Sullivan report has predicted significant growth in the South Korean biosimilars market between now and 2020.

Funding for research and treatment of brain tumours is 'lagging behind' other cancers, says a charity.

Repligen Corp. has entered into an exclusive worldwide licensing agreement with Pfizer to advance its spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Tranzyme Pharma has successfully completed its chemistry-based drug discovery collaboration with Bristol-Myers Squibb and has transferred compounds, across multiple drug targets, to BMS for further development.

GlobalData's latest report looks at the prospects for the pharmaceutical industry in Israel.

A new report looks at the potential for growth in the Chinese pharmaceutical market.

GSK has formed a partnership with Vodafone to harness innovative mobile technology to help vaccinate more children against common infectious diseases in Africa.

Decision Resources has published its latest predictions for the epilepsy drug market through 2021.

GATC Biotech customers can expect highest quality standards for Next Generation Sequencing projects from official accreditation

A new report suggests that more and more pharmaceutical companies are devoting dedicated budgets to health economics and outcomes research.

Ranbaxy, Inc., a subsidiary of India’s Ranbaxy Laboratories Ltd., has initiated a voluntary recall of 41 affected lots of Atorvastatin Calcium tablets (10 mg, 20 mg and 40 mg), a generic of Pfizer’s Lipitor.

German company Schott has announced plans to increase its production capacity in Russia by more than 50 per cent.

Aspireo Receives Positive Opinion from EMA for Orphan Disease Designation for Somatoprim

GSK has offered to increase its stake in GSK Consumer Healthcare in India.

The NEOMED Institute is a new public-private partnership between biopharmaceutical companies and the Quebec government.

A growing number of biopharmaceutical products have cold chain requirements, according to IMARC Group's latest report.

A new report by PwC has highlighted the challenges faced by pharmaceutical companies if they are to succeed beyond 2020.

TechNavio's latest report looks at the potential for growth in the diabetes drugs market.

The Department of Biotechnology (DBT) is planning to set up two advanced institutes for research including an Institute of Chronic Disease and Biotechnology.

The Medicines and Healthcare Products Agency (MHRA) is having consultations with the pharma industry and clinical research organisations (CROs) about the European Commission’s proposal to have a new clinical trials regulation.

Definiens AG, the leader in image analysis for Digital Pathology, today announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman.

A US health regulator has recommended the approval of GlaxoSmithKline's new bird flu vaccine.

The European Medicines Agency supports World Diabetes Day, which is taking place on Wednesday 14 November 2012.

Sun Pharma will acquire DUSA Pharmaceuticals in a deal worth approximately $230 million.

Boehringer Ingelheim has entered into a manufacturing agreement with Molecular Partners

A completely new way of delivering anti-cancer drugs to tumours, using 'minicells' derived from bacteria, has been tested for the first time in humans and found to be safe, well-tolerated and even induced stable disease in patients with advanced, incur...

Decision Resources' latest report looks at the prostate cancer drug market between now and 2021.

There is a strong and growing market for drugs to treat the eye diseases AMD and DR, analysts say

Healthcare reforms will remain on the agenda in the US after Barrack Obama wins a second term as president.

Takeda has announced the acquisition of Envoy Therapeutics for $140 million.

Claris, Otsuka Pharmaceutical and Mitsui have entered into a new joint venture.

The WIN Consortium has confirmed Pfizer as its first pharmaceutical partner.

Novasep intends to build the world's largest chromatography facility for pharmaceutical work.

Patient adherence to medication could be improved by adopting a more patient-centric approach, a report suggests.

The head of the ABPI has expressed concern at the UK's falling expenditure on new medicines.

Watson has sold its Rugby OTC product trademark and assets to the Harvard Drug Group.

Bayer has struck a deal to acquire US vitamin maker Schiff.

BioRx has been added to the distribution network for Zemaira.

Celgene enjoyed healthy profits in the third quarter of 2012

Sanofi will continue development of Prednisporin, but expects to sub-licence the work to a third-party.

Pharmaceuticals have been told to centralise their compliance efforts for greater success.

There are concerns that the downward trend in R&D investment in the US could jeopardise the country's global competitiveness.

Charles River Laboratories and AstraZeneca have reached a three-year agreement to deliver toxicology, safety pharmacology and development DMPK studies.

Forest Laboratories and moksha8 have announced a broad strategic alliance for Latin America.

A team in Iran have produced a prototype gum with an acceptable taste that could help to deliver the motion sickness drug dimenhydrinate more rapidly.

A new report has highlighted a slight downward trend in mergers and acquisitions.

A number of autologous cell therapies are expected to reach the market by 2017, fuelling an impressive growth rate over the next few years.

A new TechNavio report has looked at the state of the global enzyme inhibitor market and its prospects for growth

The diabetes drug market is looking robust thanks to a large pipeline of new products and an ever-increasing patient population.

The federal government in Australia has been urged to consider introducing longer patent terms for innovative medicines.

Expanded Finished Product Manufacturing Facilities Ready for Increased Licaps® Production

A new distributor contract has been signed between Injex Pharma and Medicia.

New excipients will be on show at a pharmaceuticals event in Madrid later this month.

SMARTSOURCING™ Agreement Strengthens Existing Relationship

BASF has announced the opening of a global dermatology lab in New York where topical formations will be developed for the pharmaceutical market.

Brazil's national medicines regulator has pushed back the implementation of proposed new rules that would govern the manufacturing of excipients.

PANREAC specialized in the manufacturing of reagents for laboratory analysis, excipients and bulk chemicals to be used as raw materials in the pharmaceutical, cosmetic and food industries.

Panreac Synthesis is the business unit of PANREAC, the Spanish leader company in manufacturing reagents, solvents and fine chemicals since 1941.

TransCelerate BioPharma is a non-profit organisation set up by ten biopharmaceutical giants.

Cardiolynx Ltd., specializing in the development of improved cardio-metabolic therapies, announces that the European Patent Office (EPO) has granted a patent covering a new chemical entity, CLC-1280, developed using Cardiolynx' nitric oxide technology.

Mucosis B.V., the Dutch clinical-stage biotechnology company developing mucosal vaccines, today announced the appointment of Thomas Johnston to the position of Chief Executive Officer, effective immediately.

The European Medicines Agency has been formally notified by RepliGen Europe Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicine SecreFlo (secretin human).

At its September 2012 meeting, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) elected Professor Bruno Sepodes from Portugal as its chair and Ms Lesley Greene, a volunteer patient representative for Eurordis, as its vice-...

The European Medicines Agency has revised the rules on fees payable to the Agency.

The European Medicines Agency congratulates Dr Stella Blackburn, the Agency's Risk Management Development and Scientific Lead, for her appointment as president of the International Society for Pharmacoepidemiology (ISPE).

The European Medicines Agency’s recently established Pharmacovigilance Risk Assessment Committee (PRAC) has elected June Raine (pictured) from the United Kingdom (UK) as its chair and álmath Spooner from Ireland as its vice-chair at its second mee...

Landmark drug patent protection cases involving Bayer, Roche, and Novartis are advancing in India this month. Together, they will help determine how friendly the country is to Western pharmaceutical makers.

One of Europe’s leading CMOs, Aesica, has announced a key addition to its commercial team as it looks to strengthen its position in North America.

A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.

The US Food and Drug Administration has approved Pfizer's Bosulif, used to treat a rare type of leukaemia usually suffered by older adults.

The US Food and Drug Administration has questioned the efficacy of Novartis' experimental cystic fibrosis drug tobramycin ahead of an advisory panel meeting this week.

Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced an innovative new synthesis platform for peptide researchers at the 2012 European Peptide Symposium in Athens, Greece...

Many companies now have people working full-time on companion diagnostics for use alongside targeted therapies.

A new partnership between Pfizer and Mylan should help to drive generic utilisation in Japan.

Cutting Edge Information has shed light on pharmaceutical companies' MSL spend.

The president of Peru's pharmaceutical industry association has predicted that exports will surpass $50 million this year.

Consumers and national healthcare systems make significant savings as a result of generic medicines usage, a report has confirmed.

Saladax Biomedical has expanded its existing relationship with Bristol-Myers Squibb by entering into a Master Early Development Collaboration Agreement.

Gilead and its partners in India aim to improve access to affordable antiretroviral therapy for HIV patients in developing countries.

The American health care system saved more than $1 trillion through the use of generic medicines over the last decade.

The end of patent protection has hit Irish pharmaceutical exports to the US in the first half of the year, new figures show.

Suzhou Connect hopes to advance novel small molecule compounds for the treatment of allergic rhinitis and atopic dermatitis.

The newly founded company will develop the mGluR programs from lead optimization up to clinical Phase I and seek partnership and licensing opportunities for further development.

Harvard scientists hope to develop a unique instrument that will help drug developers to assess new drug candidates.